Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 70

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 70
---
 accordance with the terms and conditions of the Merger Agreement through the Exchange Agent, the full number of MIRA Common Stock, which shall be in uncertificated book-entry form, issuable as Merger Consideration.

In addition, a warrant issued by SKNY to Bay Shore Trust (the “Warrant”) will be converted such that the shares of SKNY Common Stock exercisable thereunder shall be converted into shares of MIRA Common Stock pursuant to the Exchange Ratio.

Completion and Effectiveness of the Merger

The Merger will be completed as promptly as practicable after all of the conditions to Closing are satisfied or waived, including the approval of the stockholders of MIRA and of SKNY, unless earlier terminated in accordance with the terms of the Merger Agreement. For more information on termination rights, see the section titled “The Merger Agreement—Termination.” MIRA and SKNY cannot predict the exact timing of the Closing because it is subject to various conditions.

| 34 |

Conditions to the Merger

The completion of the Merger is subject to customary closing conditions, including but not limited to:

| ● | SKNY                                                                                                
 shall have assets comprising any combination of cash and marketable securities with a total         
 value of at least five million U.S. dollars (US$5,000,000).                                         |
| ● | There                                                                                               
 shall be no temporary restraining order, preliminary or permanent injunction or other order         
 preventing the consummation of the Merger issued by any court of competent jurisdiction or          
 other governmental body of competent jurisdiction and that remains in effect, and no law            
 may have made the consummation of the Merger illegal.                                               |
| ● | Approval                                                                                            
 of the Merger by the stockholders of both MIRA and SKNY.                                            |
| ● | NASDAQ                                                                                              
 shall not have objected to the consummation of the Merger and issuance of the Merger Consideration. |
| ● | Receipt                                                                                             
 of all necessary regulatory approvals.                                                              |
| ● | No                                                                                                  
 material adverse changes occurring to the business or financial condition of either MIRA            
 or SKNY.                                                                                            |

SKNY Capitalization on Closing

As mentioned earlier, upon Closing, SKNY is to have assets comprising any combination of cash and marketable securities with a total value of at least five million U.S. dollars (US$5,000,000). It is expected that upon closing, SKNY will hold approximately $5 million worth of shares of Telomir Pharmaceuticals, Inc